Clinical Trial Update: Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel [Phase 3]

View source ↗

Summary

Phase 3 trial of BACMUNE (MV130) for prevention of COVID-19 in healthcare personnel was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Disease 2019

Drugs mentioned

• BACMUNE (MV130) (MV130)

Snippet

Sponsor: Inmunotek S.L. | Conditions: Covid19 | Phase 3 | Status: WITHDRAWN